Collegium Provides 2025 Financial Guidance and Business Update
08. Januar 2025 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435...
Collegium to Participate in Upcoming Investor Conferences
12. November 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Record Third Quarter 2024 Financial Results
07. November 2024 16:02 ET
|
Collegium Pharmaceutical, Inc.
– Generated Record Q3’24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca® Revenue of $53.2 Million and Record Xtampza® ER Revenue of $49.5 Million – – Achieved Q3’24...
Collegium Appoints Vikram Karnani as Chief Executive Officer
07. November 2024 16:01 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024
24. Oktober 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Completes Acquisition of Ironshore Therapeutics
04. September 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference
30. August 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
28. August 2024 08:00 ET
|
Collegium Pharmaceutical, Inc.
STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people...
Collegium Reports Second Quarter 2024 Financial Results
08. August 2024 16:01 ET
|
Collegium Pharmaceutical, Inc.
– Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2’24 GAAP Net Income of $19.6 Million,...
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
29. Juli 2024 06:00 ET
|
Collegium Pharmaceutical, Inc.
– Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year – – Transaction Expected to...